Previous close | 1.6900 |
Open | 1.6500 |
Bid | 1.4600 x 100 |
Ask | 1.5200 x 300 |
Day's range | 1.4750 - 1.6700 |
52-week range | 1.3000 - 11.9200 |
Volume | |
Avg. volume | 660,301 |
Market cap | 44.777M |
Beta (5Y monthly) | -0.60 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.8600 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 11.64 |
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, today announced that management will participate in the Jefferies Global Healthcare Conference, which is taking place at the Marriott Marquis in New York City from June 5-6, 2024, to discuss the company’s pipeline, platform, and business strategy. Participating will b
- Reported Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors - - First Patient Dosed in Phase 2a Portion of Phase 1/2a Clinical Trial of IMM-1-104; Initial Data from Multiple IMM-1-104 Phase 2a Arms Expected in 2024 - - Presented Preclinical Data at AACR Demonstrating that Combining IMM-1-104 with Chemotherapies Used in The Treatment of First-line Pancreatic Cancer Yielded Deeper and More Durable Tumor Growth Inhibition Than Ei
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...